Case Report
BibTex RIS Cite

Year 2020, Volume: 3 Issue: 1, 14 - 17, 01.01.2020

Sevil Alkan Çeviker , Harun Yıldırım , Emel Yıldız

Abstract

References

  • Cesaro S, Chinello P, Rossi L, Zanesco L. 2000. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer, 8(6): 504-505.
  • Eren Z, Gürol Y, Sönmezoğlu M, Eren HŞ, Çelik G, Kantarcı G. 2014. Probiyotik tedavisinden sonra yaşlı bir hastada gelişen Saccharomyces cerevisiae fungemisi. Mikrobiyol Bul, 48(2): 351-355.
  • Fadhel M, Patel S, Liu E, Levitt M, Asif A. 2018. Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. Med Mycol Case Rep, 23: 23–25.
  • Goldin BR, Gorbach SL. 2008. Clinicalindicationsforprobiotics: an overview. ClinInfectDis, 46(2): 96–100.
  • Guarner F, Sanders ME, Eliakim R, Fedorak R, Gangl A, Garisch J. 2017. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. https://www.worldgastroenterology.org (erişim tarihi: 09.09.2019).
  • Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JNV, Suttorp MJ, Johnsen B, Shanman R, Slusser W, Fu N, Smith A, Roth B, Polak J, Motala A, Perry T, Shekelle PG. 2011. Safety of probiotics to reduce risk and prevent or treat disease. Evid RepTechnol Assess (Full Rep), 200: 1-645.
  • Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, Berche P. 2000. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis, 19(1): 16-20.
  • Herbrecht R, Nivoix Y.2005. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis, 40(11): 1635-1637.
  • Kara I, Yıldırım F, Özgen Ö, Erganiş S, Aydoğdu M, Dizbay M, Gürsel G, Kalkanci A. 2018. Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient. J Mycol Med, 28(1): 218-221.
  • Kutlu T. 2011.Pre ve Probiyotikler. Türk Ped Arş, 46 (Özel Sayı): 59-64.
  • Landaburu MF, López Daneri GA, Relloso S, Zarlenga LJ, Vinante MA, Mujica MT. 2019. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. Rev Argent Microbiol, pii: S0325-7541(19)30051-3.
  • Lherm T, Monet C, Nougière B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C. 2002. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med, 28(6): 797-801.
  • Martin IW, Tonner R, Trivedi J, Miller H, Lee R, Liang X, Rotello L, Isenbergh E, Anderson J, Perl T, Zhang SX. 2017. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis, 87(3):286-288.
  • Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, Rincón C, Hortal J, Peláez T. 2005. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis, 40(11): 1625-1634.
  • Packey CD, Ciorba MA. 2010. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol, 26(2): 88-94.
  • Roy U, Jessani LG, Rudramurthy SM, Gopalakrishnan R, Dutta S, Chakravarty C, Jillwin J, Chakrabarti A. 2017. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses, 60(6): 375-380.
  • Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Teggi A. 2014. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopath Ph, 143–146.
  • URL1: Probiotics for gastrointestinal diseases. https://www.uptodate.com/contents/probiotics-for-gastrointestinal-diseases 2018, (erişim tarihi: 9 Eylül 2019).

Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report

Year 2020, Volume: 3 Issue: 1, 14 - 17, 01.01.2020

Sevil Alkan Çeviker , Harun Yıldırım , Emel Yıldız

Abstract

Probiotics are generally prescribed as an adjuvant in the treatment of antibiotic-associated diarrhea caused by Clostridium difficile and are considered a safe preparation. Recently, however, there have been reports in the literature about fungemia that develop after probiotic treatment, especially in immunosuppressive patients. In this article, we aimed to present a patient who received chemotherapy for gastric cancer, developed fungemia after Saccharomyces boulardii probiotic treatment and required intensive care.

Keywords

Saccharomyces boulardii Probiotic Fungemia

References

  • Cesaro S, Chinello P, Rossi L, Zanesco L. 2000. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer, 8(6): 504-505.
  • Eren Z, Gürol Y, Sönmezoğlu M, Eren HŞ, Çelik G, Kantarcı G. 2014. Probiyotik tedavisinden sonra yaşlı bir hastada gelişen Saccharomyces cerevisiae fungemisi. Mikrobiyol Bul, 48(2): 351-355.
  • Fadhel M, Patel S, Liu E, Levitt M, Asif A. 2018. Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. Med Mycol Case Rep, 23: 23–25.
  • Goldin BR, Gorbach SL. 2008. Clinicalindicationsforprobiotics: an overview. ClinInfectDis, 46(2): 96–100.
  • Guarner F, Sanders ME, Eliakim R, Fedorak R, Gangl A, Garisch J. 2017. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. https://www.worldgastroenterology.org (erişim tarihi: 09.09.2019).
  • Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JNV, Suttorp MJ, Johnsen B, Shanman R, Slusser W, Fu N, Smith A, Roth B, Polak J, Motala A, Perry T, Shekelle PG. 2011. Safety of probiotics to reduce risk and prevent or treat disease. Evid RepTechnol Assess (Full Rep), 200: 1-645.
  • Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, Berche P. 2000. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis, 19(1): 16-20.
  • Herbrecht R, Nivoix Y.2005. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis, 40(11): 1635-1637.
  • Kara I, Yıldırım F, Özgen Ö, Erganiş S, Aydoğdu M, Dizbay M, Gürsel G, Kalkanci A. 2018. Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient. J Mycol Med, 28(1): 218-221.
  • Kutlu T. 2011.Pre ve Probiyotikler. Türk Ped Arş, 46 (Özel Sayı): 59-64.
  • Landaburu MF, López Daneri GA, Relloso S, Zarlenga LJ, Vinante MA, Mujica MT. 2019. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. Rev Argent Microbiol, pii: S0325-7541(19)30051-3.
  • Lherm T, Monet C, Nougière B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C. 2002. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med, 28(6): 797-801.
  • Martin IW, Tonner R, Trivedi J, Miller H, Lee R, Liang X, Rotello L, Isenbergh E, Anderson J, Perl T, Zhang SX. 2017. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis, 87(3):286-288.
  • Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, Rincón C, Hortal J, Peláez T. 2005. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis, 40(11): 1625-1634.
  • Packey CD, Ciorba MA. 2010. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol, 26(2): 88-94.
  • Roy U, Jessani LG, Rudramurthy SM, Gopalakrishnan R, Dutta S, Chakravarty C, Jillwin J, Chakrabarti A. 2017. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses, 60(6): 375-380.
  • Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Teggi A. 2014. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopath Ph, 143–146.
  • URL1: Probiotics for gastrointestinal diseases. https://www.uptodate.com/contents/probiotics-for-gastrointestinal-diseases 2018, (erişim tarihi: 9 Eylül 2019).
There are 18 citations in total.

Details

Primary Language Turkish
Subjects ​Internal Diseases
Journal Section Case Report
Authors

Sevil Alkan Çeviker 0000-0003-1944-2477

Harun Yıldırım 0000-0002-9161-263X

Emel Yıldız 0000-0003-4493-2099

Publication Date January 1, 2020
Submission Date July 13, 2019
Acceptance Date September 23, 2019
Published in Issue Year 2020 Volume: 3 Issue: 1

Cite

APA Alkan Çeviker, S., Yıldırım, H., & Yıldız, E. (2020). Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. Black Sea Journal of Health Science, 3(1), 14-17.
AMA Alkan Çeviker S, Yıldırım H, Yıldız E. Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. BSJ Health Sci. January 2020;3(1):14-17.
Chicago Alkan Çeviker, Sevil, Harun Yıldırım, and Emel Yıldız. “Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces Boulardii Fungemia in a Patient Receiving Cancer Chemotherapy: Case Report”. Black Sea Journal of Health Science 3, no. 1 (January 2020): 14-17.
EndNote Alkan Çeviker S, Yıldırım H, Yıldız E (January 1, 2020) Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. Black Sea Journal of Health Science 3 1 14–17.
IEEE S. Alkan Çeviker, H. Yıldırım, and E. Yıldız, “Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report”, BSJ Health Sci., vol. 3, no. 1, pp. 14–17, 2020.
ISNAD Alkan Çeviker, Sevil et al. “Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces Boulardii Fungemia in a Patient Receiving Cancer Chemotherapy: Case Report”. Black Sea Journal of Health Science 3/1 (January 2020), 14-17.
JAMA Alkan Çeviker S, Yıldırım H, Yıldız E. Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. BSJ Health Sci. 2020;3:14–17.
MLA Alkan Çeviker, Sevil et al. “Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces Boulardii Fungemia in a Patient Receiving Cancer Chemotherapy: Case Report”. Black Sea Journal of Health Science, vol. 3, no. 1, 2020, pp. 14-17.
Vancouver Alkan Çeviker S, Yıldırım H, Yıldız E. Immunosuppressive Patient Problem in Probiotic Use: Saccharomyces boulardii fungemia in a patient receiving cancer chemotherapy: Case Report. BSJ Health Sci. 2020;3(1):14-7.
 Download Cover Image